未登录

R

Renguo Guan

southern medical university - china

H指数:16

被引数:1,089

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Assessment of Tumor Burden Score as a Feasible and Reliable Tool for Prognosis Prediction for Hepatocellular Carcinoma Undergoing Hepatectomy: A Multicenter, Retrospective Study

JOURNAL OF HEPATOCELLULAR CARCINOMA

IF3.4

2025-02-010

OAAI

Prognosis prediction of α-FAtE score for locoregional immunotherapy in hepatocellular carcinoma

FRONTIERS IN IMMUNOLOGY

IF5.9

2025-01-100

OAAI

Oxaliplatin induces pyroptosis in hepatoma cells and enhances antitumor immunity against hepatocellular carcinoma

BRITISH JOURNAL OF CANCER

IF6.8

2025-01-020

PRE

Patients with hepatocellular carcinoma extrahepatic metastases can benefit from hepatic arterial infusion chemotherapy combined with lenvatinib plus programmed death-1 inhibitors

INTERNATIONAL JOURNAL OF SURGERY

IF10.1

2024-07-014

OAAI

Hepatic Arterial Infusion Chemotherapy vs Transcatheter Arterial Chemoembolization as Adjuvant Therapy Following Surgery for MVI-Positive Hepatocellular Carcinoma: A Multicenter Propensity Score Matching Analysis

JOURNAL OF HEPATOCELLULAR CARCINOMA

IF3.4

2024-04-012

OAAI

Hepatic arterial infusion chemotherapy versus transarterial chemoembolization, potential conversion therapies for single huge hepatocellular carcinoma: a retrospective comparison study

INTERNATIONAL JOURNAL OF SURGERY

IF10.1

2023-08-147

OAAI

Is the CRAFITY score a superior predictor of prognosis and adverse events in hepatocellular carcinoma patients treated with locoregional-immunotherapy?

HEPATOLOGY INTERNATIONAL

IF6.1

2023-05-0213

PRE

Nomograms for predicting the recurrence probability and recurrence-free survival in patients with hepatocellular carcinoma after conversion hepatectomy based on hepatic arterial infusion chemotherapy: a multicenter, retrospective study

INTERNATIONAL JOURNAL OF SURGERY

IF10.1

2023-05-014

OAAI

Comparative efficacy of PD-1 inhibitors plus lenvatinib and regorafenib after lenvatinib failure for advanced hepatocellular carcinoma: a real-world study

HEPATOLOGY INTERNATIONAL

IF6.1

2023-01-075

PRE

Nomogram Based on Inflammatory Biomarkers to Predict the Recurrence of Hepatocellular Carcinoma-A Multicentre Experience

inflammation research

IF4.1

2022-09-018

OA

Four-gene signature predicting overall survival and immune infiltration in hepatocellular carcinoma by bioinformatics analysis with RT-qPCR validation

通过生物信息学分析和rt-qpcr验证四基因签名预测肝细胞癌的总体生存和免疫浸润

IF3.4

2022-07-302

OAAI

The pyroptosis-related gene signature predicts prognosis and indicates immune activity in hepatocellular carcinoma

MOLECULAR MEDICINE

IF6.4

2022-02-0558

OAAI

Pan-cancer analysis of the CASP gene family in relation to survival, tumor-infiltrating immune cells and therapeutic targets

IF3

2020-11-0132

OAAI

RETRACTED: The cross-talk between DDR1 and STAT3 promotes the development of hepatocellular carcinoma (Retracted Article)

IF3.9

2020-07-2725

OA

Identification of Aberrantly Methylated Differentially CpG Sites in Hepatocellular Carcinoma and Their Association With Patient Survival

FRONTIERS IN ONCOLOGY

IF3.3

2020-07-233

OAAI

Long non-coding RNA DLGAP1-AS1 facilitates tumorigenesis and epithelial-mesenchymal transition in hepatocellular carcinoma via the feedback loop of miR-26a/b-5p/IL-6/JAK2/STAT3 and Wnt/β-catenin pathway

CELL DEATH & DISEASE

IF9.6

2020-01-1676

OAAI

Assessment of the expression of the immune checkpoint molecules PD-1, CTLA4, TIM-3 and LAG-3 across different cancers in relation to treatment response, tumor-infiltrating immune cells and survival

评估不同癌症中免疫检查点分子PD-1，CTLA4，TIM-3和LAG-3的表达与治疗反应，肿瘤浸润性免疫细胞和生存率的关系

INTERNATIONAL JOURNAL OF CANCER

IF4.7

2019-12-02132

OAAI

Genome-Wide Profiling of Prognostic Alternative Splicing Pattern in Pancreatic Cancer

胰腺癌预后选择性剪接模式的全基因组分析

FRONTIERS IN ONCOLOGY

IF3.3

2019-08-2726

OAAI